3-Nonanoyloxirane-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: 3-Nonanoyloxirane-2-carboxamide
• 化学式: C₁₂H₂₁NO₃
• 分子量: 227.3
• InChiKey: OKJJXKSUEUHANI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel compounds, pharmaceutical compositions containing same, and methods of use for same
  申请人：Kuhajda P. Francis

  公开号：US20060247302A1

  公开（公告）日：2006-11-02

  A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R 21 ═H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CH 2 OR 25 , —C(O)R 25 , —CO(O)R 25 , —C(O)NR 25 R 26 , —CH 2 C(O)R 25 , or —CH 2 C(O)NHR 25 , where R 25 and R 26 are each independently H, C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R 22 ═—OH, —OR 27 , —OCH 2 C(O)R 27 , —OCH 2 C(O)NHR 27 , —OC(O)R 27 , —OC(O)OR 27 , —OC(O)NHNH—R 5 , or —OC(O)NR 27 R 28 , where R 27 and R 28 are each independently H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R 27 and R 28 can each optionally contain halogen atoms; R 23 and R 24 , the same or different from each other, are C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.

  一种制药组合物，包括一种制药稀释剂和一种公式IV的化合物，其中R21═H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基、—CH2OR25、—C（O）R25、—CO（O）R25、—C（O）NR25R26、—CH2C（O）R25或—CH2C（O）NHR25，其中R25和R26各自独立地为H、C1-C10烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，可选含有一个或多个卤素原子；R22═—OH、—OR27、—OCH2C（O）R27、—OCH2C（O）NHR27、—OC（O）R27、—OC（O）OR27、—OC（O）NHNH—R5或—OC（O）NR27R28，其中R27和R28各自独立地为H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，且R27和R28均可选含有卤素原子；R23和R24相同或不同，为C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基。使用这种配方的方法包括用于治疗癌症、减轻体重、治疗微生物感染、抑制神经肽Y和/或脂肪酸合成酶以及刺激CPT-1。
• NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME
  申请人：Kuhajda Francis P.

  公开号：US20100029752A1

  公开（公告）日：2010-02-04

  A pharmaceutical composition containing a pharmaceutical diluent and a compound of formula II: wherein: R 8 ═H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —C(O)R 4 , where R 4 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, or —OH, —OR 7 or —NR 7 , where R 7 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R 9 =—OR 5 , —NR 5 , —NH—NH—R 5 where R 5 is H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, allyl, or alkylaryl, optionally containing halogen atoms; R 10 ═H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or —CH 2 C(O)R 6 , where R 6 is OR 7 and NR 7 , where R 7 ═H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, allyl, or alkylaryl and can optionally contain halogen atoms. Also included in the invention are methods of using the pharmaceutical compositions and the chemical compounds used in the compositions.

  一种含有药物稀释剂和二式化合物的药物组合物，其中：R8═H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，—C（O）R4，其中R4为H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，可选地含有卤素原子，或—OH、—OR7或—NR7，其中R7为H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，可选地含有卤素原子；R9=—OR5、—NR5、—NH—NH—R5，其中R5为H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基、烯丙基或烷基芳基，可选地含有卤素原子；R10═H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基或烷基芳基，或—CH2C（O）R6，其中R6为OR7和NR7，其中R7═H、C1-C20烷基、环烷基、烯基、芳基、芳基烷基、烯丙基或烷基芳基，可选地含有卤素原子。发明还包括使用药物组合物和组合物中使用的化学化合物的方法。
• Factor XIIIa inhibitor compounds useful for thrombolytic therapy
  申请人：MERCK & CO. INC.

  公开号：EP0294016A2

  公开（公告）日：1988-12-07

  Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.

  现已发现某些因子 XIIIa 抑制剂化合物可用于溶解血凝块，因此可单独或与纤溶酶原激活剂一起用于溶栓治疗。
• Compositions and methods for inhibiting platelet activation and thrombosis
  申请人：Beth Israel Deaconess Medical Center

  公开号：US20040147540A1

  公开（公告）日：2004-07-29

  The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The invention additionally relates to the use of protein palmitoylation inhibitors for the reduction of platelet activation, platelet aggregation and thrombosis, as well as to the use of protein palmitoylation as a target for the identification of inhibitors of platelet activation, platelet aggregation and thrombosis.

  本发明提供了减少血小板活化、血小板聚集和血栓形成的方法和组合物。本发明进一步提供了用于治疗或预防疾病或失调的组合物和方法，其中疾病或失调的病理涉及血小板活化、血小板聚集和血栓形成中的一种或多种。本发明还涉及使用蛋白棕榈酰化抑制剂降低血小板活化、血小板聚集和血栓形成，以及使用蛋白棕榈酰化作为靶点鉴定血小板活化、血小板聚集和血栓形成抑制剂。
• EP1534263A4
  申请人：——

  公开号：EP1534263A4

  公开（公告）日：2006-10-11